CURE’s Chronic Lymphocytic Leukemia (CLL) page features the latest cancer news and updates on CLL Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in chronic lymphocytic leukemia.
This article was sponsored by AstraZeneca.
An interview with Dr. Jennifer K. Lue, Assistant Professor of Medicine, Center for Lymphoid Malignancies, Division of Hematology and Oncology, Columbia University Irving Medical Center
December 19th 2018
The combination use of Imbruvica (ibrutinib) with Rituxan (rituximab) significantly improved survival outcomes compared with standard of care in younger patients with chronic lymphocytic leukemia (CLL).
December 19th 2018
Former NFL coach discusses how cancer motivated him to appreciate life.
December 18th 2018
Single agent Copiktra (duvelisib) induced robust, durable responses in patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who experienced disease progression after treatment with Arzerra (ofatumumab).
December 14th 2018
Frontline use of Imbruvica (ibrutinib) in combination with Gazyva (obinutuzumab) significantly reduced the risk for disease progression or death among patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), especially in those with high-risk disease.
December 8th 2018
This week, we spoke with former NFL coach, motivational speaker and acute promyelocytic leukemia survivor Chuck Pagano about his journey with cancer, and what has inspired him to give back following his diagnosis.
December 7th 2018
In patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), high doses of curcumin and vitamin D could help stabilize the disease, according to new research presented at the American Society of Hematology’s (ASH) Annual Meeting in San Diego.
December 4th 2018
Administering Imbruvica with CAR-T cell therapy improved outcomes in patients with chronic lymphocytic leukemia, according to recent research.
December 3rd 2018
Regimens containing Imbruvica bested chemoimmunotherapy treatments in elderly patients with chronic lymphocytic leukemia, but less toxic and long-term treatments are still needed.
December 3rd 2018
An oncologist and three advocates were honored for their work on behalf of people with chronic lymphocytic leukemia.
November 20th 2018
While CAR-T cell therapy has potential in treating CLL, T-cell fatigue and toxicity still raise many concerns.
November 19th 2018
CLL is the most common type of leukemia in adults across the United State. Here's what you need to know about the disease.
November 18th 2018
What’s the best plan for lowering cancer drug prices? A panel of experts debated the possibilities.
November 12th 2018
Imbruvica (ibrutinib) is a safe treatment for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL), according to a pooled analysis of four clinical trials.
November 10th 2018
Chronic lymphocytic leukemia can now be managed as a long-term condition, and there are new ways loved ones can help.
October 17th 2018
The FDA has granted a priority designation to a supplemental new drug application (sNDA) for Imbruvica (ibrutinib) for use in combination with Gazyva (obinutuzumab) for the frontline treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
September 25th 2018
The drug was approved for adults with chronic lymphocytic leukemia and small lymphocytic lymphoma. And was granted an accelerated approval for follicular lymphoma.
September 7th 2018
Equipping with knowledge to improve patient-physician communication and understanding the disease.
August 26th 2018
An expert provides tips for maximizing time with your oncologist and adhering to oral medication.
August 11th 2018
Better treatment options have put chronic lymphocytic leukemia in the spotlight in recent years. But just what is CLL?
June 8th 2018
The Food and Drug Administration (FDA) approved Venclexta (venetoclax) in combination with Rituxan (rituximab) for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without the genetic mutation 17p deletion, who have received at least one prior therapy.
April 13th 2018
A new drug combination bested current standard of care in a clinical trial.
April 9th 2018
The Food and Drug Administration (FDA) granted duvelisib a priority review to a new drug application (NDA) for full approval to treat patients who have relapsed or refractory chronic lymphocytic leukemia or small lymphocytic leukemia (CLL/SLL). The FDA also granted an accelerated approval for the treatment of patients with relapsed or refractory follicular lymphoma.
March 4th 2018
Survey finds quality of life and cost affect treatment decisions.
January 30th 2018
William G. Wierda, M.D., Ph.D., medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses how to best combine and sequence therapies for patients with chronic lymphocytic leukemia (CLL).
December 26th 2017
The CLL Society is a nonprofit organization that serves the CLL community by offering a platform for patients and caregivers to receive education and support, as well as information on cutting-edge research and treatment options.
December 25th 2017
While patients with chronic lymphocytic leukemia (CLL) tend to have long life expectancies, with many prescribed to a “watch-and-wait” approach, a recent study by the Cancer Support Community (CSC) found that more than half of patients living with the disease reported that having CLL affects their viewpoints regarding their life expectancy.
September 25th 2017
OVER THE LAST FEW years, significant advances were made in the treatment of patients with chronic lymphocytic leukemia (CLL). Several novel therapies, most of them oral, have now been approved by the Food and Drug Administration. These include Imbruvica (ibrutinib), a Bruton’s tyrosine kinase (BTK) inhibitor; Venclexta (venetoclax), a B-cell lymphoma-2 (BCL2) inhibitor; and Zydelig (idelalisib), a phosphoinositide 3-kinase (PI3K) inhibitor.